Protocol Ledger

NCT06239311 · Phase III · RECRUITING

Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.

Interventional Phase III clinical trial protocol NCT06239311 sponsored by medac in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-02-27 Enrollment: 277 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06239311
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)277 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06239311
Protocol FieldVerified Registry Value
NCT IdentifierNCT06239311
Consolidated Lead Sponsormedac
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment277 participants (ESTIMATED)
Registered Start Date2024-02-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06239311
Hospital Research SiteLocationSite Profile
Centre Hospitalier Lyon SudPierre-Bénite, FranceOpen Hospital Dossier ->
Azienda Ospedaliero Universitaria di ParmaParma, ItalyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI